Does the Time to Start First-Line Treatment Influence the Survival of Favorable-Risk Patients With Metastatic Renal Cell Carcinoma? Results of the MetaSurv-UroCCR 79 Study.
Fiche publication
Date publication
juillet 2022
Journal
Clinical genitourinary cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe
Tous les auteurs :
Rolley C, Barthelemy P, Bensalah K, Nouhaud FX, Villers A, Bruyère F, Lebdai S, Ricard S, Gross-Goupil M, Rouprêt M, Bernhard JC, Bigot P
Lien Pubmed
Résumé
Many patients in the favorable International Metastatic renal cell carcinoma (RCC) Data Base Consortium group (F-MRC) may have a relatively indolent disease course. Surveillance and delay of systemic therapy could be an option in this specific population. However, the question whether this delay could alter patients' outcome remains unanswered. Our objective was to determine if delaying first-line treatment influences the survival of F-MRC patients.
Mots clés
Delayed treatment, Favorable IMDC group, First line treatment, Metastatic renal cell carcinoma
Référence
Clin Genitourin Cancer. 2022 07 9;: